Evidence map›Paper›PMID 35233014›Full record

Trial reportScientific reports2022

SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.

Grant A Kay, Sophie I Owen, Emanuele Giorgi, David J Clark, Christopher T Williams, Stefanie Menzies, Luis E Cuevas, Benedict M O Davies, Nicholas M Eckersley, Grant L Hughes and 6 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Grant A KayCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Sophie I OwenCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Emanuele GiorgiCentre for Health Informatics Computing and Statistics, Lancaster University Medical School, Lancaster University, Lancaster, UK.
David J ClarkCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Christopher T WilliamsCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Stefanie MenziesCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Luis E CuevasCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.
Benedict M O DaviesCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Nicholas M EckersleyCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Grant L HughesDepartments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK.
Daniela E KirwanCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Sanjeev KrishnaCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Edward I PattersonDepartments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK.
Tim PlancheCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Henry M StainesCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK. hstaines@sgul.ac.uk.
Emily R AdamsCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK. Emily.Adams@lstmed.ac.uk.
Liverpool School of Tropical Medicine · GBSt George's, University of London · GBLancaster University · GBSt George’s University Hospitals NHS Foundation Trust · GB

Funding

Medical Research Council MR/P019978/1Medical Research Council MR/P019978/2Wellcome Trust 204809/Z/16/ZWellcome Trust 220764/Z/20/Z
6 · The paper itself

Abstract

Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8-99.9] sensitive and 88.9% [95% CI 51.8-99.7] specific at predicting the presence of NAbs (PRNT

Indexed as

Neutralization TestsAgedAntibodies, ViralCOVID-19Enzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralImmunoglobulin GImmunoglobulin MSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35233014
PMCPMC8888744
OpenAlexW4214678712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.